Effects of growth hormone therapy on bone mass, metabolic balance, and well-being in young adult survivors of childhood acute lymphoblastic leukemia

Journal of Pediatric Hematology/Oncology

Volumn 33, Issue 6, 2011, Pages

  Van Den Heijkant, Silvia ^a   Hoorweg Nijman, Gera ^b   Huisman, Jaap ^c   Drent, Madeleine ^c   Van Der Pal, Heleen ^d   Kaspers, Gert Jan ^c   Van De Waal, Henriette Delemarre ^e  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

adult survivors; ALL; body composition; bone density; growth hormone therapy; psychological well being

Indexed keywords

CORTICOSTEROID; CYTARABINE; HUMAN GROWTH HORMONE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; SOMATOMEDIN C; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BLOATING; BODY COMPOSITION; BODY FAT; BODY HEIGHT; BONE DENSITY; BONE MASS; CANCER SURVIVOR; CENTRAL NERVOUS SYSTEM METASTASIS; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FEMUR NECK; GROWTH HORMONE DEFICIENCY; HORMONAL THERAPY; HUMAN; JOINT STIFFNESS; LEAN BODY WEIGHT; LUMBAR SPINE; MALE; METABOLIC BALANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; SKIN TINGLING; SKULL IRRADIATION; TREATMENT DURATION; WELLBEING;

ADULT; BONE DENSITY; CHILD; FEMALE; HEALTH STATUS; HUMAN GROWTH HORMONE; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL RATE; SURVIVORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051749813     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31821bbe7a     Document Type: Article

References (56)

1. Pui CP, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178. (Pubitemid 43076714)
2. Jarfelt M, Bjarnason R, Lannering B. Young adult survivors of childhood acute lymphoblastic leukemia: Spontaneous GH secretion in relation to CNS radiation. Pediatr Blood Cancer. 2004;42:582-588. (Pubitemid 38669745)
3. Brennan BM, Rahim A, Mackie EM, et al. Growth hormone status in adults treated for acute lymphoblastic leukemia in childhood. Clin Endocrinol (Oxf). 1998;48:777-783. (Pubitemid 28289248)
4. Stubberfield TG, Byrne GC, Jones TW. Growth and growth hormone secretion after treatment for acute lymphoblastic leukemia in childhood. 18-Gy versus 24-Gy cranial irradiation. J Pediatr Hematol Oncol. 1995;17:167-171.
5. Melin AE, Adan L, Leverger G, et al. Growth hormone secretion, puberty and adult height after cranial irradiation with 18 Gy for leukemia. Eur J Pediatr. 1998;157:703-707. (Pubitemid 28419094)
6. Hoorweg-Nijman JJ, Kardos G, Roos JC, et al. Bone mineral density and markers of bone turnover in young adult survivors of childhood lymphoblastic leukemia. Clin Endocrinol (Oxf). 1999;50:237-244. (Pubitemid 29100012)
7. Brennan BM, Rahim A, Adams JA, et al. Reduced bone mineral density in young adults following cure of acute lymphoblastic leukemia in childhood. Br J Cancer. 1999;79: 1859-1863. (Pubitemid 29132316)
8. Thomas IH, Donohue JE, Ness KK, et al. Bone mineral density in young adult survivors of acute lymphoblastic leukemia. Cancer. 2008;113:3248-3256.
9. van der Sluis IM, van den Heuvel-Eibrink MM, Hahlen K, et al. Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukemia in childhood. Med Pediatr Oncol. 2000;35:415-420.
10. Arikoski P, Komulainen J, Voutilainen R, et al. Reduced bone mineral density in long-term survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1998;20: 234-240. (Pubitemid 28280900)
11. van der Sluis IM, van den Heuvel-Eibrink MM, Hählen K, et al. Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia. J Pediatr. 2002;141:204-210.
12. Leung W, Rose SR, Zhou Y, et al. Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia. J Clin Oncol. 2002;20:2959-2964. (Pubitemid 34728890)
13. Zebrack BJ, Zeltzer LK, Whitton J, et al. Psychological outcomes in long-term survivors of childhood leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma: A report from the Childhood Cancer Survivor Study. Pediatrics. 2002;110:42-52. (Pubitemid 34742639)
14. Oeffinger KC, Nathan PC, Kremer LCM. Challenges after curative treatment for childhood cancer and long-term follow-up of survivors. Pediatr Clin North America. 2008;55: 251-273. (Pubitemid 351173184)
15. Mattson E, Lindgren B, Von Essen L. Are there any positive consequences of childhood cancer? A review of the literature. Acta Oncol. 2008;47:199-206.
16. Zeltzer LK, Lu Q, Leisenring W, et al. Psychosocial outcomes and health-related quality of life in adult childhood cancer survivors: A report from the Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev. 2008;17:435-446. (Pubitemid 351272798)
17. Gurney JG, Krull KR, Kadan-Lottick N, et al. Social outcomes in the Childhood Cancer Survivor Study Cohort. J Clin Oncol. 2009;27:2390-2395.
18. Soares CN, Musolino NR, Cunha Neto M, et al. Impact of recombinant human growth hormone (RH-GH) treatment on psychiatric, neuropsychological and clinical profiles of GH deficient adults. A placebo-controlled trial. Arq Neuropsiquiatr. 1999;57:182-189. (Pubitemid 29247147)
19. Huisman J, Aukema EJ, Deijen JB, et al. The usefulness of growth hormone treatment for psychological status in young adult survivors of childhood leukemia: An open-label study. BMC Pediatr. 2008;20:1-8.
20. Zeltzer LK, Recklitis C, Buchbinder D, et al. Psychological status in childhood cancer survivors: A report from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27: 2396-2404.
21. Radcliffe DJ, Pliskin JS, Silvers JB, et al. Growth hormone therapy and quality of life in adults and children. Pharmacoeconomics. 2004;22:499-524. (Pubitemid 38858294)
22. Faust M, Strasburger CJ. Growth hormone therapy in adults? Attempts to assess a decade of use. Internist (Berl). 2008;49: 527-537.
23. Deijen JB, van der Veen EA. The influence of growth hormone (GH) deficiency and GH replacement on quality of life in GHdeficient patients. J Endocrinol Invest. 1999;22:127-136.
24. Eiser C, Vance YH, Glaser A, et al. Growth hormone treatment and quality of life among survivors of childhood cancer. Horm Res. 2005;63:300-304. (Pubitemid 41159843)
25. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: Summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab. 1998;83:379-381.
26. Curran SL, Andrykowski MA, Studts JL. Short form of the Profile of Mood States (POMS-SF): Psychometric information. Psychological Assessment. 1995;7:80-83.
27. Wald FDM, Mellenbergh GJ. De verkorte versie van de Nederlandse vertaling van de Profile of Moods States. Nederlands Tijdschrift voor de Psychologie. 1990;45:86-90.
28. Van der Ploeg HM, Defares PB, Spielberger CD. Handleiding bij de Zelf Beoordelings Vragenlijst, ZBV. Lisse: Swets and Zeitlinger; 1980.
29. Gough HG. Manual for the California Psychological Inventory. Palo Alto, Calif.: Consulting Psychologists Press; 1964.
30. Luteijn F, Starren J, van Dijk H. Handleiding Nederlandse Persoonlijkheids Vragenlijst. Lisse: Swets and Zeilinger; 1985.
31. Derogatis LR. SCL-90: Administration, Scoring and Procedures Manual-I for the R(evised) Version. Johns Hopkins University School of Medicine, Clinical Psychometrics Research Unit. Baltimore. 1977.
32. Arrindel WA, Ettema H. Dimensionele structuur, betrouwbaarheid en validiteit van de Nederlandse bewerking van de Symptom Checklist (SCL-90); gegevens gebaseerd op een fobische en een "normale" populatie. Nederlands Tijdschrift voor Psychologie. 1981;36:77-108.
33. Wasilewski-Masker K, Kaste SC, Hudson MM, et al. Bone mineral density deficits in survivors of childhood cancer: Longterm follow-up guidelines and review of the literature. Pediatrics. 2008;121:705-712.
34. Vassilopoulou-Sellin R, Brosnan P, Delpassand A, et al. Osteopenia in young adult survivors of childhood cancer. Med Pediatr Oncol. 1999;32:272-278. (Pubitemid 29147101)
35. Nysom K, Holm K, Fleischer Michaelsen K, et al. Bone mass after treatment for acute lymphoblastic leukemia in childhood. J Clin Oncol. 1998;16:3752-3760. (Pubitemid 29001526)
36. Kaste SC, Jones-Wallace D, Rose SR, et al. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: Frequency of occurrence and risk factors for their development. Leukemia. 2001;15:728-734. (Pubitemid 32492695)
37. Mandel K, Atkinson S, Barr RD, et al. Skeletal morbidity in childhood acute lymphoblastic leukemia. J Clin Oncol. 2004;22:1215-1221. (Pubitemid 41079834)
38. Barr RD, Simpson T, Webber CE, et al. Osteopenia in children surviving brain tumours. Eur J Cancer. 1998;34:873-877. (Pubitemid 28248499)
39. Murray RD, Darzy KH, Gleeson HK, et al. GH-deficient survivors of childhood cancer: GH replacement during adult life. J Clin Endocrinol Metab. 2002;87:129-135. (Pubitemid 34084681)
40. Nussey SS, Hyer SL, Brada M, et al. Bone mineralization after treatment of GH deficiency in survivors of childhood malignancy. Acta Paediatr. 1994;399:9-14.
41. Drake WM, Rodríguez-Arnao J, Weaver JU, et al. The influence of gender on the short and long-term effects of growth hormone replacement and bone mineral density in hypopituitary adults: A 5-year study. Clin Endocrinol. 2001;54: 525-532. (Pubitemid 34207705)
42. Schonau E. The development of the skeletal system in children and the influence of muscular strength. Horm Res. 1998;49: 27-31. (Pubitemid 28008977)
43. Bulow B, Link K, Ahren B, et al. Survivors of childhood acute lymphoblastic leukemia, with radiation-induced GH deficiency, exhibit hyperleptinaemia and impaired insulin sensitivity, unaffected by 12 months of GH treatment. Clin Endocrinol (Oxf). 2004;61:683-691. (Pubitemid 40011843)
44. Jarfelt M, Lannering B, Bosaeus I, et al. Body composition in young adult survivors of childhood acute lymphoblastic leukemia. Eur J Endocrinol. 2005;153:81-89. (Pubitemid 41030519)
45. Ness KK, Baker KS, Dengel DR, et al. Body composition, muscle strength deficits and mobility limitations in adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007;49:975-981. (Pubitemid 350022455)
46. Kuromaru R, Kohno H, Hara T. Changes in adiposity and excess body weight correlate with growth responses but not with decreases in low-density lipoprotein cholesterol levels during GH treatment in GH-deficient children. Clin Endocrinol (Oxf). 2002;56:799-803. (Pubitemid 34785913)
47. Darzy KH, Aimaretti G, Wieringa G, et al. The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J Clin Endocrinol Metab. 2003;88:95-102. (Pubitemid 36115149)
48. Underwood LE, Attie KM, Baptista J, et al. Growth hormone dose-response in young adults with childhood-onset GH deficiency: A two year, multicenter, multiple-dose, placebocontrolled study. J Clin Endocrinol Metab. 2003;88:5273-5280. (Pubitemid 37452727)
49. Corneli G, Somma di C, Baldelli R, et al. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol. 2005;153;257-153;264.
50. Link K, Moëll C, Garwicz S, et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab. 2004;89:5003-5012. (Pubitemid 39391441)
51. Watanabe S, Mizuno S, Oshima LH, et al. Leukemia and other malignancies among GH users. J Pediatr Endocrinol. 1993;6: 99-108. (Pubitemid 23192352)
52. Grumbach MM, Bin-Abbas BS, Kaplan SL. The growth hormone cascade: Progress and long-term results of growth hormone treatment in growth hormone deficiency. Horm Res. 1998;49:41-57.
53. Ogilvy-Stuart AL, Gleeson H. Cancer risk following growth hormone use in childhood: Implications for current practice. Drug Saf. 2004;27:369-382. (Pubitemid 38608456)
54. Wyatt D. Lessons from the national cooperative growth study. Eur J Endocrinol. 2004;151:55-59.
55. Blethen SL. Complications of growth hormone therapy in children. Curr Opin Pediatr. 1995;7:466-471.
56. Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab. 2006;91:3494-3498. (Pubitemid 44402126)